Sugi Predict

Sugi Predict / Compounds / Anisperimus

Anisperimus

Anisperimus

SCHEMBL8778920

C[C@@H](N)CCNCCCCNC(=O)OCC(=O)NCCCCCCNC(=N)N

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.39
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ALOX15 P16050 1/20 0.33
▸ ITGB3 P05106 1/20 0.33
▸ ITGA2B P08514 1/20 0.33
▸ ACHE P22303 7/20 0.33
▸ EPHX1 P07099 1/20 0.31
▸ HDAC3 O15379 2/20 0.31
▸ HDAC4 P56524 2/20 0.31
▸ HDAC1 Q13547 2/20 0.31
▸ HDAC7 Q8WUI4 2/20 0.31
▸ HDAC2 Q92769 2/20 0.31
▸ HDAC10 Q969S8 2/20 0.31
▸ HDAC11 Q96DB2 2/20 0.31
▸ HDAC8 Q9BY41 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anisperimus SCHEMBL8778901 1.00 FAAH (0.39) FAAHMAOAMAOBMEN1CYP1A2
Anisperimus SCHEMBL8778912 1.00 FAAH (0.39) FAAHMAOAMAOBMEN1CYP1A2
Anisperimus SCHEMBL8778892 0.92 NPY4R (0.36) FAAHMAOAMAOBMEN1CYP1A2
Anisperimus SCHEMBL8923118 0.92 NPY4R (0.36) FAAHMAOAMAOBMEN1CYP1A2
Anisperimus SCHEMBL8778895 0.92 NPY4R (0.36) FAAHMAOAMAOBMEN1CYP1A2
Anisperimus SCHEMBL29406187 0.86 MEN1 (0.40) FAAHMEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL526029 0.86 MEN1 (0.38) MAOAMAOBMEN1CYP1A2KMT2A
SCHEMBL8778890 0.86 MEN1 (0.38) MAOAMAOBMEN1CYP1A2KMT2A
SCHEMBL8779131 0.86 MEN1 (0.38) MAOAMAOBMEN1CYP1A2KMT2A
SCHEMBL9017339 0.83 FAAH (0.40) FAAHMAOAMAOBMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0669316-B1 Analogs of 15-deoxyspergualine, process for their preparation and their use as immunosuppressive agents FOURNIER IND & SANTE (FR) 1997-07-30 — — EP claimed
EP-0669316-A1 Analogs of 15-déoxyspergualine, process for their preparation and their use as immunosuppressive agents FOURNIER INDUSTRIE ET SANTE (FR) 1995-08-30 — — EP claimed
US-12409191-B2 Renal cell populations and uses thereof PROKIDNEY (KY) 2025-09-09 — — US disclosed
EP-3901251-B9 RENAL CELL POPULATIONS AND USES THEREOF PROKIDNEY (KY) 2025-06-18 — — EP disclosed
US-20250152632-A1 RENAL CELL POPULATIONS AND USES THEREOF ProKidney IPCo, LLC (KY) 2025-05-15 — — US disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 — — EP disclosed
EP-4527921-A2 RENAL CELL POPULATIONS AND USES THEREOF ProKidney (KY) 2025-03-26 — — EP disclosed
EP-3901251-B1 RENAL CELL POPULATIONS AND USES THEREOF PROKIDNEY (KY) 2024-12-25 — — EP disclosed
US-20240409941-A1 BIOACTIVE RENAL CELLS ProKidney IPCo, LLC (KY) 2024-12-12 — — US disclosed
US-12157887-B2 Bioactive renal cells PROKIDNEY (KY) 2024-12-03 — — US disclosed
EP-4403197-A2 INJECTABLE FORMULATIONS FOR ORGAN AUGMENTATION ProKidney (KY) 2024-07-24 — — EP disclosed
US-20110104186-A1 Small molecule immunopotentiators and assays for their detection NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2011-05-05 — — US disclosed
US-20110086416-A1 IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-04-14 — — US disclosed
US-20110086416-A1 IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-04-14 — — US disclosed
US-7776829-B2 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases EURO NIPPON KAYAKU GMBH (DE) 2010-08-17 — — US disclosed
US-7776829-B2 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases EURO NIPPON KAYAKU GMBH (DE) 2010-08-17 — — US disclosed
US-7696338-B2 Immunotoxin fusion proteins and means for expression thereof THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2010-04-13 — — US disclosed
US-7696338-B2 Immunotoxin fusion proteins and means for expression thereof THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2010-04-13 — — US disclosed
EP-0669316-B1 Analogs of 15-deoxyspergualine, process for their preparation and their use as immunosuppressive agents FOURNIER IND & SANTE (FR) 1997-07-30 — — EP disclosed
EP-0669316-A1 Analogs of 15-déoxyspergualine, process for their preparation and their use as immunosuppressive agents FOURNIER INDUSTRIE ET SANTE (FR) 1995-08-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086416-A1 IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF CD74, CD2, ANTXR2 FAAH 3568/4885MAOA 3795/4885MAOB 3790/4885
US-20110104186-A1 Small molecule immunopotentiators and assays for their detection ICOS, CD14, MAVS FAAH 4191/4885MAOA 2770/4885MAOB 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.